# NCT05384626 (NCT05384626)

> A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05384626
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Nuvalent Inc.
- Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor
- Interventions: Neladalkib (NVL-655); Midazolam; Repaglinide; Itraconazole
- Enrollment: 840
- Primary outcome: Dose limiting toxicities (DLTs) (Phase 1)
- Primary outcome: Recommended Phase 2 Dose (RP2D) (Phase 1)
- Primary outcome: Objective Response Rate (ORR) (Phase 2)
- Primary outcome: Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1)
- Primary outcome: Area under the curve of repaglinide (Phase 2 DDI sub-study)
- Primary outcome: Area under the curve of midazolam (Phase 2 DDI sub-study)
- Primary outcome: Area under the curve of neladalkib (NVL-655) (Phase 2 DDI sub-study)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05384626